Medicamen Biotech Limited — Important, 03-06-2025: General Updates

Medicamen Biotech has announced a board meeting to approve the financial results for the quarter and half-year. The company received its first USFDA ANDA approval for Bortezomib 3.5 mg injection, developed via in-house R&D and made at its USDMF-certified API facility. This milestone enhances its presence in the regulated US market and supports growth in vertically integrated drug manufacturing.